# Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients

> **NCT02327689** · PHASE4 · UNKNOWN · sponsor: **Asian-Pacific Alliance of Liver Disease, Beijing** · enrollment: 400 (estimated)

## Conditions studied

- Hepatitis B, Chronic
- Fibrosis

## Interventions

- **DRUG:** Emtricitabine plus adefovir dipivoxil

## Key facts

- **NCT ID:** NCT02327689
- **Lead sponsor:** Asian-Pacific Alliance of Liver Disease, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2015-07
- **Final completion:** 2017-07
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2014-12-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02327689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02327689, "Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02327689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*